Discovering SIGA Technologies And 2 Other Compelling Penny Stocks

In the last week, the market has been flat, but over the past 12 months, it has risen by 27%, with earnings forecasted to grow by 17% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for growth at lower price points when backed by strong balance sheets and solid fundamentals. In this article, we explore several compelling penny stocks that stand out as hidden gems in today's market landscape.

Let's dive into some prime choices out of the screener.

SIGA Technologies (SIGA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SIGA Technologies, Inc. is a commercial-stage pharmaceutical company that operates in the health security market in the United States with a market cap of $322.04 million.

Operations: The company's revenue is primarily derived from its Pharmaceuticals segment, totaling $93.78 million.

Market Cap: $322.04M

SIGA Technologies, Inc. presents a mixed picture for penny stock investors. With a market cap of US$322.04 million and revenue from its Pharmaceuticals segment at US$93.78 million, the company is not pre-revenue but faces challenges such as declining earnings over recent years and reduced profit margins from 40.3% to 21.6%. Despite this, SIGA remains debt-free with strong short-term asset coverage of liabilities and high-quality earnings reported in the past year. Recent financial results show a net loss increase to US$3.45 million in Q1 2026, highlighting ongoing volatility but also potential growth opportunities with forecasted earnings increases ahead.

• Click here and access our complete financial health analysis report to understand the dynamics of SIGA Technologies.
• Explore SIGA Technologies' analyst forecasts in our growth report.

Marqeta (MQ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Marqeta, Inc. operates a cloud-based open API platform for card issuing and transaction processing services in the United States, with a market cap of approximately $1.70 billion.

Operations: The company's revenue is primarily derived from its data processing segment, which generated $651.61 million.

Market Cap: $1.7B

Marqeta, Inc. showcases a complex profile for penny stock investors. With a market cap of US$1.70 billion and revenue from data processing at US$651.61 million, it is not pre-revenue but faces challenges such as low return on equity at 0.3% and declining profit margins from 10.4% to 0.3%. Despite negative earnings growth over the past year, Marqeta has become profitable over five years with no debt concerns and strong asset coverage of liabilities. Recent executive changes, notably Lukasz Strozek's appointment as CTO, may influence its technology strategy moving forward amid forecasted revenue growth expectations.

• Click here to discover the nuances of Marqeta with our detailed analytical financial health report.
• Understand Marqeta's earnings outlook by examining our growth report.

Blend Labs (BLND)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Blend Labs, Inc. offers a cloud-based software platform for financial services firms in the United States, India, and Mexico with a market cap of approximately $370.44 million.

Operations: The company's revenue primarily comes from its Blend Platform segment, which generated $127.58 million.

Market Cap: $370.44M

Blend Labs, Inc. presents a nuanced opportunity within the penny stock landscape. The company, with a market cap of approximately US$370.44 million and revenue from its Blend Platform segment at US$127.58 million, is not pre-revenue but remains unprofitable with recent net losses narrowing to US$8.05 million in Q1 2026 from US$9.52 million a year prior. Despite this, it maintains strong asset coverage over liabilities and is debt-free, offering financial stability amidst volatility in share price and management turnover challenges. Recent product innovations like Autopilot MCP may enhance operational efficiencies for lending clients, potentially influencing future growth trajectories.

• Unlock comprehensive insights into our analysis of Blend Labs stock in this financial health report.
• Gain insights into Blend Labs' future direction by reviewing our growth report.

Make It Happen

• Unlock more gems! Our US Penny Stocks screener has unearthed 342 more companies for you to explore.Click here to unveil our expertly curated list of 345 US Penny Stocks.
• Searching for a Fresh Perspective? We've found 10 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com